

ACT EU Multi-stakeholder Platform Meeting Clinical Research Investment Plan

20 March 2026

Romina Escobar

*Policy Officer at the European Commission,
Directorate-General for Research & Innovation at the
European Commission*





FOR LIFE SCIENCES

A Strategy
for European
Life Sciences



European Life Sciences Strategy


- Adopted by the European Commission in July 2025 ⁽¹⁾.
- It announces several flagship actions ⁽²⁾.

Reinforcing European R&I:

- Flagship Action: Clinical Research
Investment Plan (2026)

⁽¹⁾ EU LSS: eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52025DC0525

⁽²⁾ Horizon Europe Work Programme Cluster 1 – Health: 4. Health



Our aim is to ...**Position the EU as the world's most attractive place for life sciences** by...

Optimising the R&I ecosystem for a **globally competitive** life science sector

Boosting the trust, uptake and use of life science innovation



2030

Ensuring **smooth and rapid market access** for life science innovations

Revitalising Europe's Clinical Research Ecosystem

Life sciences are critical for EU competitiveness and strategic autonomy

- **Draghi Report (2024)**
- **Letta Report (2024)**
- **Start-up & Scale-up Agenda (2025)**

How Europe Can Lead

- Act as one ecosystem
- Invest in talent and networks
- Use digital & AI tools

Alignment with ACT EU Key Performance Indicators (KPIs) & activities

Exploratory analysis on funding to support academic sponsors conduct multi-national clinical trials

New targets for clinical trials in Europe | European Medicines Agency (EMA)

CLINICAL RESEARCH INVESTMENT PLAN



Flagship action announced in the European Life Sciences Strategy **expected** in 2026

Main focus:

- Facilitate **funding** for multi-country clinical trials, in compliance with competition rules.
- Further develop and streamline **European research infrastructures** in the field of clinical research.

Non-regulatory initiative complementing regulatory measures.

Vision: Advancing towards a single market for clinical research.

Targeted Consultations - Engagement with Stakeholders

- **Events:**

Clinical Research Investment Plan Workshop - 15 December 2025

Horizon Europe Health Programme Committee Workshop - 5 February 2026

- **Dedicated meetings:**

Hospitals with high clinical trial activity

Entities supporting Innovation & Health Investors

European Research Infrastructures supporting clinical research

- **Upcoming Meetings:**

Consultation meeting with Patients' Organisations (TBC)

Discussion Topics:

- Funding Models: Innovative approaches involving both public and private funding
- Single-Entry Point or One-stop-shop for Clinical Trials
- Infrastructure Support for multi-national trials
- SME Support
- Artificial Intelligence & Use of Data

Some recommendations from the consultations

- Consensus on the need to develop more agile funding instruments for clinical trials. They should blend public, private, and philanthropic funding.
- Successful national models demonstrate the value of a single-entry point to connect sponsors with existing national infrastructures and networks.
- SMEs face barriers in accessing funding and support required for multi-country clinical trials. A single-entry or one-stop approach could ease these issues, supported by public procurement and payer engagement.
- Artificial intelligence was identified as a transformative enabler for clinical research, offering potential for cost reduction and improved trial processes.
- Need to address information asymmetries regarding existing available support and funding routes via an EU-level info portal
- Need for a dedicated stakeholder platform, which would include all relevant players in the discussion (therapeutics, MedTech, big and small players)
- Need to address disinformation and promote participation in clinical studies

THANK YOU!

Romina Escobar - Romina-Belen.ESCOBAR-RAMOS@ec.europa.eu

